Immunogen (IMGN) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
October 27, 2015 6:30 AM EDTConference Call Today at 8:00 am ET
Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGens novel folate receptor (FR)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November. Patient enrollment completed in Phase 1 ovarian cancer cohort that ImmunoGen plans to discuss with regulators in 2016. Company on track to initiate trials designed to potentially support an Accelerated Approval pathway (FORWARD I) and market expansion (FORWARD II) for mirvetuximab soravtansine. Broader pipeline progress includes advancement of another... More